SecBot SecBot
20-F ·Filed May 29, 2026

RDY

DR REDDYS LABORATORIES LTD
NEUTRAL
Impact 2/10
Horizonweeks Processed5mo ago SEC0001575872-26-000381
Notable filing: 20-F
Actionable Insight • Neutral

This is a routine annual filing with no new material information. Traders should focus on the Q4 FY2026 earnings call transcript (filed May 18, 2026) for any operational updates. The 20-F itself provides no immediate trading catalyst.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$13.26
T+0 close · May 29, 2026 · via day close
Latest settled
−6.94%
T+60 · $12.34
Vs SPY
−8.17%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 1 $13.26entry
  2. T+1 · 6mo ago −1.73%α −1.88% · $13.03
  3. T+5 · 5mo ago −0.15%α +2.60% · $13.24
  4. T+20 · 5mo ago +9.28%α +10.57% · $14.49
  5. T+60 · 3mo ago −6.94%α −8.17% · $12.34

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dr. Reddy's filed its annual Form 20-F for the fiscal year ended March 31, 2026, a routine annual report with no new material financial disclosures beyond what was previously reported in its Q4 FY2026 earnings. The filing confirms 834,656,970 equity shares outstanding and the company's status as a large accelerated filer. No material changes, restatements, or going-concern issues are noted.

Key Facts

  • Annual report for fiscal year ended March 31, 2026, filed on Form 20-F
  • 834,656,970 equity shares outstanding as of March 31, 2026
  • Company confirms it is a large accelerated filer and has filed all required reports
  • No restatements, error corrections, or going-concern issues disclosed
  • Financial statements prepared under IFRS as issued by IASB
  • Convenience translation rate: US$1 = Rs. 93.83 as of March 31, 2026

Financial Impact

No new financial figures disclosed in this filing beyond previously reported Q4 FY2026 results

Risk Factors

  • Risk factors disclosed include pricing pressure, regulatory inspections, patent litigation, and geopolitical instability in Russia/Ukraine and Middle East
  • U.S. FDA issued a complete response letter for biosimilar rituximab BLA in November 2024; additional response submitted February 2026 with no approval timeline certainty
  • Potential impact from U.S. executive order on most-favored-nation drug pricing (May 12, 2025) remains uncertain

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
50% bullish (44 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
20-F Filing (Primary)0001575872-26-000381
Document: 0001575872-26-000381-index.html0001575872-26-000381
Document: 0001575872-26-000381.txt0001575872-26-000381

Track record

73 reports on RDY

Performance horizon

7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 7 of 12 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
  2. Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
  3. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
  4. Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
  5. Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
  6. Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
  7. Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  8. Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  9. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
  10. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
Showing 10 of 73

US Market Status

Market Closed · Opens in 5h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 29, 2026